Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tornado diagram of one-way deterministic sensitivity analysis.

Published byかげたつ まきい Modified over 5 years ago

Similar presentations

Presentation on theme: "Tornado diagram of one-way deterministic sensitivity analysis."— Presentation transcript:

1 Tornado diagram of one-way deterministic sensitivity analysis.
Tornado diagram of one-way deterministic sensitivity analysis. Numbers are the estimated ICER when changing parameter value to a maximal value (light grey) or a minimal value (dark grey). Only parameters giving variation above €200 are shown. BMS, bare-metal stent; DES, drug-eluting stent; ICER, incremental cost-effectiveness ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; ST, stent thrombosis. Louise Baschet et al. Open Heart 2016;3:e000445 ©2016 by British Cardiovascular Society

Download ppt "Tornado diagram of one-way deterministic sensitivity analysis."

Similar presentations

Figure 1 Flow diagram of systematic review

Figure 1 Flow diagram of systematic review
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.

Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
The MASS-DAC Study.

The MASS-DAC Study.
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;

Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
Supplementary Table 1 Independent Predictors of 2-Year Mortality

Supplementary Table 1 Independent Predictors of 2-Year Mortality
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
Copyright © 2013 American Medical Association. All rights reserved.

Copyright © 2013 American Medical Association. All rights reserved.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Markov model structure

Markov model structure
Circ Cardiovasc Interv

Circ Cardiovasc Interv
Glenn N. Levine et al. JACC 2016;68:

Glenn N. Levine et al. JACC 2016;68:
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Perioperative management of antiplatelet therapy

Perioperative management of antiplatelet therapy
BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.
J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K

J. Trevor Posenau, MD, Daniel M. Wojdyla, MS, Linda K
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 

Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Similar presentations

Ads by Google